Overview
Lobbying Costs
1,000,000€ - 1,249,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
3.3 Fte (13)
Lobbyists with EP accreditation
4
High-level Commission meetings
10
Lobbying Costs over the years
-
Info
Novo Nordisk A/S
EU Transparency Register
29570313329-11 First registered on 13 Mar 2010
Goals / Remit
Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat. We employ more than 60,000 people in 80 countries, and market our products in 170 countries. In 2023, we served more than 40 million patients worldwide. In 2023, we served more than 6 million patients in the EU. More than 30,000 of our employees are based in the EU. Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line).The controlling stake in Novo Nordisk is owned by the Novo Nordisk Foundation. This is a non-profit institution, whose formal purpose is to provide a stable basis for its companies’ operations and to make contributions to scientific, humanitarian and social progress.
Main EU files targeted
EU pharmaceutical-related policy, as well as broader health, environmental and business-related policy.
Address
Head Office
Novo Nordisk A/SNovo Allé, 1
Bagsværd 2880
DENMARKEU Office
Square de Meeûs 35
Brussels 1000
BELGIUMWebsite
-
People
Total lobbyists declared
13
Employment time Lobbyists 75% 2 50% 1 25% 2 10% 8 Lobbyists (Full time equivalent)
3.3
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
4 accreditations were / are live (in bold) for the selected state of 17 Feb 2025
Name Start date End Date Alexander Von Wildenrath LØVGREEN 26 Nov 2024 26 Nov 2025 Cecilie Fenger Michaelsen 25 Nov 2024 25 Nov 2025 Marie Hjortdal Nielsen 08 Apr 2024 08 Apr 2026 Helen Oberg 08 Apr 2024 08 Apr 2026 Matthew Thomas Vincent CLAY 27 Oct 2023 04 Oct 2024 Alexander Von Wildenrath LØVGREEN 08 Apr 2024 22 Nov 2024 Ms Helen Oberg 12 Apr 2023 26 Apr 2024 Mr Christian JUUL NYHUS 16 Feb 2023 16 Feb 2024 Mr Alexander VON WILDENRATH LØVGREEN 16 Feb 2023 16 Feb 2024 Mr Matthew CLAY 07 Jun 2022 07 Jun 2023 Mr Vincent CLAY 07 Jun 2022 27 Jun 2022 Jeppe Torp VESTENTOFT 03 Dec 2019 01 Aug 2020 Ms Victoria Breck 30 Nov 2019 28 Nov 2020 Ms Ane Sofie Böhm Nielsen 23 Sep 2014 19 Sep 2015 Mr Troels Anders RYE-ANDERSEN 08 Aug 2014 06 Aug 2015 Mr Morten Frank Pedersen 19 Sep 2013 18 Sep 2014 Ms Engelbertha Maria Rouweler 17 Sep 2013 14 Mar 2014 Mr Neil David Causey 17 Sep 2013 14 Sep 2014 Mr Troels Anders RYE-ANDERSEN 07 Jun 2013 06 Jun 2014 Mr Troels Anders RYE-ANDERSEN 16 Jan 2012 08 Feb 2013 Complementary Information
A range of Novo Nordisk colleagues contribute their expertise to activities covered by the Register, directly or through trade associations. We have used 10% relevant working time as the threshold for including colleagues in our FTE calculations.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Novo Nordisk is member of:
- EFPIA - European Federation of Pharmaceutical Industries and Associations
- Danish Chamber of Commerce (Dansk Erhverv)
- Danish industry (Dansk industri)
- Science|Business NetworkMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
1,000,000€ - 1,249,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount acumen 25,000€ - 49,999€ trade council, ministry of foreign affairs, denmark 10,000€ - 24,999€ fipra 50,000€ - 99,999€ copenhagen economics 50,000€ - 99,999€ rud pedersen 50,000€ - 99,999€ politico europe 25,000€ - 49,999€ Intermediaries for current year
Name copenhagen economics rud pedersen politico europe acumen public affairs Closed year Costs
1,000,000€ - 1,249,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
N/A
Communication activities
The LinkedIn account of our CEO, Lars Fruergaard Jørgensen, may sometimes include content relevant to activities covered by the Register: https://www.linkedin.com/in/larsfruergaard/
Novo Nordisk sponsored Politico Brussels Playbook during the week of 20 February 2023
In November 2023, Politico Europe published sponsored content from EFPIA, authored by Lars Fruergaard Jørgensen in his role as EFPIA President: https://www.politico.eu/sponsored-content/the-future-for-europe-and-the-role-of-medical-innovation/Other activities
Novo Nordisk's goals with its involvement with EU institutions are:
- to improve conditions for prevention, treatment and care in Europe to address unmet needs
- to support the voice of people living with or at risk of developing serious chronic diseases
- to increase Europe´s competitiveness as a location for Research and DevelopmentMeetings
Meetings
10 meetings found. Download meetings
The list below covers meetings with Commissioners/Cabinet members/Directors-general (high-level) Commission meetings published December 2014 to December 2024, and the meetings of Commissioners/Cabinet members/Directors-general and officials holding "management functions" in the Commission published since 1 January 2025. Other lobby meetings with lower-level staff may well have taken place, but the Commission doesn't proactively publish information about these meetings. All information below comes from the Commission and not from the registrant.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 05 Feb 2025 Location Brussels, ORBN Subject Meeting with Novo Nordisk Chief Scientific Advisor to discuss how research and innovation can help Europe to meet the ambitions set out in the Competitiveness Compass. DG Research and Innovation Attending - Marc Lemaître (Director-General)
-
Date 05 Feb 2025 Location Brussels Subject Exchange of views on life sciences research and innovation Cabinet Cabinet of Commissioner Ekaterina Zaharieva Attending - Elena Martines (Cabinet member)
- Ann-Sofie Ronnlund (Cabinet member)
-
Date 22 Jan 2025 Location Switzerland, Davos Subject Economic State of play of sector Cabinet Cabinet of Executive Vice-President Stéphane Séjourné Attending - Stéphane Séjourné (Executive Vice-President)
- Ioan-Dragos Tudorache (Cabinet member)
Other Lobbyists -
Date 17 Jan 2024 Location Davos Subject Meeting with Ms Camilla Sylvest, Executive Vice-President. Cabinet Cabinet of Commissioner Stella Kyriakides Attending - Stella Kyriakides (Commissioner)
- Giorgios Rossides (Cabinet member)
-
Date 30 Mar 2023 Location Brussels, Belgium Subject The discussion will be focused on the up-coming legislation on plants produced by certain genomic techniques, and the revision of plant-proteins. Cabinet Cabinet of Commissioner Janusz Wojciechowski Portfolio Agriculture Attending - Jorge Pinto Antunes (Cabinet member)
Other Lobbyists -
Date 06 Dec 2022 Location Brussels Subject Revision of the EU pharmaceutical legislation. Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Pierre-Arnaud Proux (Cabinet member)
-
Date 16 Sep 2021 Location Brussels Subject Discussion with EFPIA and Novo Nordisk on how the pharmaceutical industry could contribute to the EU's agenda for open strategic autonomy and the renewed industrial strategy and on the green transformations of the pharmaceutical sector. DG Internal Market, Industry, Entrepreneurship and SMEs Attending - Kerstin Jorna (Director-General)
-
Date 16 Jun 2021 Location online Subject Supply chains for medicines Cabinet Cabinet of Vice-President Margaritis Schinas Portfolio Promoting the European Way of Life Attending - Margaritis Schinas (Vice-President)
- Maria Luisa Llano Cardenal (Cabinet member)
Other Lobbyists - MEDICINES FOR EUROPE
- Leuphana Universität Lüneburg
- The European Association of Hospital Pharmacists
- Fresenius Kabi Deutschland GmbH
- Bureau Européen des Unions de Consommateurs
- Teva Pharmaceuticals Europe BV
- European Chemical Industry Council
- SANOFI
- Pfizer Inc.
- European Patients' Forum (EPF)
- Phamaceutical Group of the European Union
- Medichem, S.A.
- European Federation of Pharmaceutical Industries and Associations
- European Healthcare Distribution Association
-
Date 21 May 2021 Location Copenhagen Subject Industrial Strategy Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Margrethe Vestager (Executive Vice-President)
Other Lobbyists -
Date 25 Jan 2021 Location Brussels Subject Commission’s priorities for digital and industrial policy in 2021 Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Christiane Canenbley (Cabinet member)
- Michele Piergiovanni (Cabinet member)
Other Lobbyists